Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Multiplex Assays Detect HSV-1/2 And Varicella Zoster Virus

By LabMedica International staff writers
Posted on 12 Jan 2015
The performance of two multiplex real-time polymerase chain reactions (PCR) to individual real-time PCR for the detection of herpes simplex virus-1 (HSV-1), HSV-2, and Varicella zoster virus (VZV) from clinical specimens have been compared.

Viral culture has been considered the gold standard test, although molecular methods have been shown to be more rapid and sensitive and currently, most laboratories perform real-time PCR for the detection of HSV and VZV.

Scientists at the Mayo Clinic (Rochester, MN, USA) tested 26,186 samples that were submitted to their laboratory for routine testing by HSV-1/2 real-time PCR analyte-specific reagents (ASR) and/or a VZV laboratory-developed test (LDT) between November 2013 and March 2014. Testing by the routine methods included nucleic acid extraction using the MagNA Pure (Roche; Basel, Switzerland) and analysis on the Roche LightCycler 2.0.

The two multiplex assays that were compared to the routine PCR were the US Food and Drug Administration (FDA; Silver Springs, MD, USA)-approved Lyra HSV 1+2/VZV assay (Quidel; San Diego, CA, USA) and the Simplexa HSV-1/2 and VZV combined analyte specific reagents (Focus Diagnostics; Cypress, CA, USA). Samples were also tested by combining the Focus Diagnostics ASRs for HSV 1 + 2 and VZV and testing was then performed on the Focus 3M Integrated Cycler.

The results were compared to a consensus standard, defined as the result obtained by at least two of the three molecular methods. The sensitivity of the Quidel assay ranged from 92.0% for HSV-1 to 97.7% for HSV-2, while the specificity for all targets was 100%. The Focus assay demonstrated 100% sensitivity for all targets, and the percent specificity ranged from 96.8% for HSV-1 to 100% for HSV-2 and VZV.

The authors concluded that for the detection of HSV-2 in cerebrospinal fluid (CSF), the Focus assay showed 100% sensitivity and specificity, while the Quidel HSV-2 method exhibited a sensitivity of 87.5% (7/8) and specificity of 100% (18/18). Future studies evaluating a larger number of CSF samples are needed to better define the performance of these tests. Multiplex assays for HSV-1/2 and VZV offer a promising option for clinical laboratories seeking to reduce hands-on and turnaround times. The study was published online in the January issue of the journal Diagnostic Microbiology and Infectious Disease.

Related Links:

Mayo Clinic
Roche 
Quidel



Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Auto Clinical Chemistry Analyzer
cobas c 703
New
HIV-1 Test
HIV-1 Real Time RT-PCR Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The experimental blood test accurately indicates severity and predicts potential recovery from spinal cord injury (Photo courtesy of 123RF)

Blood Test Identifies Multiple Biomarkers for Rapid Diagnosis of Spinal Cord Injury

The National Institutes of Health estimates that 18,000 individuals in the United States sustain spinal cord injuries (SCIs) annually, resulting in a staggering financial burden of over USD 9.... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Industry

view channel
Image: Tumor-associated macrophages visualized using the Multiomic LS Assay (Photo courtesy of ACD)

Leica Biosystems and Bio-Techne Expand Spatial Multiomic Collaboration

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded the longstanding partnership between its spatial biology brand, Advanced Cell Diagnostics (ACD, Newark, CA, USA), and Leica Biosystems (Nussloch,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.